Comparison Of Intravenous And Intrathecal Magnesium Sulphate with Spinal anaesthesia in patients undergoing lower abdominal elective surgery to study onset and duration of numbness,pain relief and stability of blood pressure and heart rate.

Comparative analysis of intrathecal and intravenous infusion of Magnesium Sulphate as adjuvant to spinal anesthesia versus spinal anesthesia with hyperbaric 0.5 percent Bupivacaine in lower abdominal elective surgeries:A prospective randomized double blinded clinical study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094977

Enrollment

135

Registered

2025-09-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Spinal Anesthesia With Intravenous Magnesium Sulphate: 200 mg Of Loading Dose Of Intravenous Magnesium Sulphate Over 10 Mins Followed By Continuous Infusion Of 500 mg Magnesium Sulphate

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients aged 18- 50 years 2) Study include both male and female 3) All lower limb abdominal surgeries under Spinal Anesthesia 4) Signed informed consent given by legally authorised representative 5) ASA Grade I and II

Exclusion criteria

Exclusion criteria: 1) Patient refusal for consent 2) Allergy to the drug 3) Patients with hypertension 4) Recent history of use of other sedatives and anxiolytics 5) Patients with history of muscle weakness and respiratory depression 6) History of spine surgeries in past, history associated with spina bifida, meningocele and meningomyelocele

Design outcomes

Primary

Measure	Time frame
Onset and duration of sensory and motor blockade following spinal anaesthesiaTimepoint: Assessed intraoperatively at 2 mins intervals until complete block and postoperatively until regression of sensory blockade (up to 6 hours)	—

Secondary

Measure	Time frame
Hemodynamic parameters(heart rate,systolic , diastolic,mean arterial pressure, oxygen saturation)Timepoint: Measured at baseline, every 5 minutes intraoperatively for the first 30 minutes, then every 15 minutes until the end of surgery, & postoperatively at 30 min, 1 hr, 2 hr, 4 hr, & 6 hr.;Duration of postoperative analgesia (time from intrathecal injection to first rescue analgesic request)Timepoint: Assessed postoperatively until 24 hours.;Adverse effects(hypotension, bradycardia, nausea, vomiting, shivering, pruritus, respiratory depression, neurological deficits)Timepoint: Monitored intraoperatively & postoperatively for 24 hours.;Sedation(assessed using Ramsay sedation score)Timepoint: Intraoperatively every 15 minutes & postoperatively at 30 min, 1 hr, 2 hr, & 4 hr.	—

Measure

Time frame

Hemodynamic parameters(heart rate,systolic , diastolic,mean arterial pressure, oxygen saturation)Timepoint: Measured at baseline, every 5 minutes intraoperatively for the first 30 minutes, then every 15 minutes until the end of surgery, & postoperatively at 30 min, 1 hr, 2 hr, 4 hr, & 6 hr.;Duration of postoperative analgesia (time from intrathecal injection to first rescue analgesic request)Timepoint: Assessed postoperatively until 24 hours.;Adverse effects(hypotension, bradycardia, nausea, vomiting, shivering, pruritus, respiratory depression, neurological deficits)Timepoint: Monitored intraoperatively & postoperatively for 24 hours.;Sedation(assessed using Ramsay sedation score)Timepoint: Intraoperatively every 15 minutes & postoperatively at 30 min, 1 hr, 2 hr, & 4 hr.

—

Countries

India

Contacts

Public ContactDR Rampal Singh

AIIMS,Raipur

drrampalsingh@aiimsraipur.edu.in9457086753

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026